文献速递脑血管病

基于骨折风险评分优化卒中后吡格列酮治疗

Scoring System to Optimize Pioglitazone Therapy After Stroke Based on Fracture Risk.
PubMed 文献 · Stroke · 2018-12-10

该研究为IRIS试验的二次分析,针对缺血性卒中或短暂性脑缺血发作后存在胰岛素抵抗的患者,构建骨折风险评分模型并按风险分层比较吡格列酮与安慰剂的获益与风险。结果显示吡格列酮致骨折的相对风险在各层相似,但低风险组骨折绝对风险差较小,而卒中或心肌梗死风险下降不随骨折风险变化,低风险患者每致1例骨折可预防2.0例卒中或心肌梗死。

要点

  • 简单骨折风险评分可识别吡格列酮治疗获益风险比较优的低危患者
  • 低骨折风险组吡格列酮致骨折绝对风险差为1.8%,高危组为6.4%
  • 吡格列酮降低卒中或心肌梗死风险不随骨折风险分层变化

核心结论

  • 简单骨折风险点评分有助于筛选缺血性卒中或短暂性脑缺血发作后适合吡格列酮治疗、获益风险比较优的患者。

研究设计与样本

  • IRIS试验为随机安慰剂对照试验,纳入缺血性卒中或短暂性脑缺血发作180天内、有胰岛素抵抗但无糖尿病的患者。
  • 受试者来自179个国际中心,招募时间为2005年2月至2013年1月,中位随访4.8年。
  • 本研究为IRIS试验的二次分析,依据入组时患者特征建立骨折风险模型并在风险分层内比较吡格列酮与安慰剂。

主要发现

  • 骨折风险模型纳入年龄、种族-民族、性别、体质指数、残疾和用药等评分项。
  • 低危组骨折绝对风险差为1.8%(95%CI -0.7%至4.4%),高危组为6.4%(95%CI 3.2%至9.6%)。
  • 低危组卒中或心肌梗死绝对风险差为-3.7%,高危组为-3.5%,不随骨折风险变化。
  • 低危患者每致1例骨折可预防2.0例卒中或心肌梗死,高危患者为0.5例。

关键数值与推荐

  • 低骨折风险组(评分低于中位数)吡格列酮组骨折5.8%对安慰剂组4.0%,绝对风险差1.8%(95%CI -0.7%至4.4%)。
  • 高骨折风险组(评分≥中位数)吡格列酮组骨折18.0%对安慰剂组11.6%,绝对风险差6.4%(95%CI 3.2%至9.6%)。
  • 低危组卒中或心肌梗死绝对风险差-3.7%,高危组-3.5%。

临床怎么用

  • 对缺血性卒中或短暂性脑缺血发作后考虑吡格列酮治疗的患者,可先用简单点评分评估骨折风险。
  • 评分提示骨折低危者吡格列酮的净获益更有利,可作为选择治疗人群的参考。

局限性

  • 本文为IRIS试验的二次分析,骨折风险模型与分层结果需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- The insulin sensitizer, pioglitazone, reduces cardiovascular risk in patients after an ischemic stroke or transient ischemic attack but increases bone fracture risk. We conducted a secondary analysis of the IRIS trial (Insulin Resistance Intervention After Stroke) to assess the effect of pretreatment risk for fracture on the net benefits of pioglitazone therapy. Methods- IRIS was a randomized placebo-controlled trial of pioglitazone that enrolled patients with insulin resistance but without diabetes mellitus within 180 days of an ischemic stroke or transient ischemic attack. Participants were recruited at 179 international centers from February 2005 to January 2013 and followed for a median of 4.8 years. Fracture risk models were developed from patient characteristics at entry. Within fracture risk strata, we quantified the effects of pioglitazone compared with placebo by estimating the relative risks and absolute 5-year risk differences for fracture and stroke or myocardial infarction. Results- The fracture risk model included points for age, race-ethnicity, sex, body mass index, disability, and medications. The relative increment in fracture risk with pioglitazone was similar in the lower (<median point score) and higher (≥ median point score) risk strata. However, the absolute risk difference (ARD) for fracture was less in the low-risk group (5.8% in pioglitazone group versus 4.0% in placebo group; ARD, 1.8%; 95% CI, -0.7% to 4.4%) compared with high-risk group (18.0% versus 11.6%; ARD, 6.4%; 95% CI, 3.2% to 9.6%). Reductions in risk for stroke or myocardial infarction did not vary by fracture risk (low-risk ARD, -3.7%; high-risk ARD, -3.5%). In low-risk patients, pioglitazone prevented 2.0 strokes or myocardial infarctions for each fracture caused, compared with 0.5 among those at high risk. Conclusions- A simple point score identifying patients at low risk for fracture may assist in selecting patients with a favorable benefit-risk profile for pioglitazone therapy after ischemic stroke or transient ischemic attack.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Viscoli CM, Kent DM, Conwit R, et al. Scoring System to Optimize Pioglitazone Therapy After Stroke Based on Fracture Risk. Stroke. 2018. PMID: 30580725. doi:10.1161/STROKEAHA.118.022745

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。